📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Discovery of next generation HER2 antibodies for the treatment of cancer

Lead Participant: EPSILOGEN LTD

Abstract

IGEM Therapeutics Ltd aims to develop a novel HER2-targeted antibody that will address a number of unmet clinical needs. It will exploit innovative animal models, novel HER2-binding antibody domains and its innovative IgE platform technology. IgE provides a completely unique anti-cancer mode of action which enables our products to be clearly differentiated from IgG-based therapies. IGEM aims to attain a leading position in the global immune-oncology market which is forecast to reach $28 billion by 2025\.

Lead Participant

Project Cost

Grant Offer
EPSILOGEN LTD £747,453 £ 523,217

Publications

10 25 50